FMP

FMP

Enter

ETNB - 89bio, Inc.

Discounted Cash Flow Model of 89bio, Inc.(ETNB), 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercializ

photo-url-https://financialmodelingprep.com/image-stock/ETNB.png

89bio, Inc.

ETNB

NASDAQ

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

8.18 USD

-0.75 (-9.17%)

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep